After 33 years, Geron’s first approval marks a turn in Nobel-winning science

The decades-long story of how a first-in-class blood cancer treatment went from bench to bedside.

Ahead of its upcoming decision date, a competitor takes aim at KarXT

The FDA isn’t slated to render a decision about BMS and Karuna’s potential breakthrough schizophrenia med until September — but a biotech is already hoping to be hot on its heels.